Showing results (51-60 of 233) with videos related to
Sort By:
Pageof 24
American Journal of Hematology|March 31, 2022
First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysisHassan Abushukair, Sebawe Syaj, Obada Ababneh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2010
Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesBart Barlogie, Michel Attal, John Crowley, et al.Ejhaem|August 19, 2024
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamabSyed Naqvi, Asis Shrestha, Marah Alzubi, et al.British Journal of Haematology|December 11, 2019
Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcomeMeera Mohan, Niels Weinhold, Carolina Schinke, et al.British Journal of Haematology|April 7, 2009
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profileYiming Zhou, Bijay Nair, John D Shaughnessy, et al.British Journal of Haematology|February 28, 2008
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2Mauricio Pineda-Roman, Maurizio Zangari, Jeff Haessler, et al.Blood Advances|March 1, 2023
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysisFarah Mazahreh, Liyan Mazahreh, Carolina Schinke, et al.Frontiers in Immunology|August 5, 2022
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modellingJean-François Rossi, Hao-Chun Chiang, Zhao-Yang Lu, et al.Clinical Lymphoma & Myeloma|June 27, 2006
Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myelomaBart Barlogie, Maurizio Zangari, Vanessa Bolejack, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioningAshraf Badros, Bart Barlogie, Eric Siegel, et al.Pageof 24